他汀类药物肝脏安全性问题

被引:26
作者
范建高
蔡晓波
机构
[1] 上海交通大学附属第一人民医院消化内科
关键词
他汀类; 肝衰竭; 药物; NAFLD; 肝脏; 安全性问题;
D O I
暂无
中图分类号
R972 [心血管系统药物];
学科分类号
1007 ;
摘要
<正> 他汀类药物继1987年问世以来,已成为西方发达国家处方量最大的药物之一,在心脑血管疾病的防治中起着重要作用。随着"早期干预、强化降脂、长期用药"理论的提出,他汀类药物的安全性问题备受关注,当前对他汀类药物肝脏毒性的过分担忧已影响到高脂血症的常规治疗,而对安全性的正确评价则有利于风险管理和心脑血管获益。为此,本文从肝脏病学的角度客观评估他汀类药物的安全性,并探讨与高脂血症密切相关的非酒精性脂肪性肝病(nonalcoholic
引用
收藏
页码:589 / 592
页数:4
相关论文
共 12 条
[1]   亚太地区非酒精性脂肪性肝病诊疗指南 [J].
范建高 ;
蔡晓波 .
肝脏, 2007, (01) :51-52
[2]   隐源性肝炎的病因分类与处理 [J].
范建高 .
中华传染病杂志, 2003, (06) :9-12
[3]  
脂肪性肝病[M]. 人民卫生出版社 , 范建高,曾民德主编, 2005
[4]  
Statin Safety: A Systematic Review[J] . Malcolm Law,Alicja R. Rudnicka.The American Journal of Cardiology . 2006 (8)
[5]  
690 Statins in patients with elevated liver enzymes because of non-alcoholic fatty liver disease (NAFLD): A clinical and histopathological follow-up study[J] . M. Ekstedt,L.E. Franzén,U.L. Mathiesen,G. Bodemar,S. Kechagias.Journal of Hepatology . 2006
[6]   Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes [J].
Vuppalanchi, RAJ ;
Teal, E ;
Chalasani, N .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2005, 329 (02) :62-65
[7]   Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S) [J].
Strandberg, TE ;
Pyörälä, K ;
Cook, TJ ;
Wilhelmsen, L ;
Faergeman, O ;
Thorgeirsson, G ;
Pedersen, TR ;
Kjekshus, J .
LANCET, 2004, 364 (9436) :771-777
[8]  
Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study[J] . Loukianos S Rallidis,Christos K Drakoulis,Aikaterini S Parasi.Atherosclerosis . 2004 (1)
[9]   Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity [J].
Chalasani, N ;
Aljadhey, H ;
Kesterson, J ;
Murray, MD ;
Hall, SD .
GASTROENTEROLOGY, 2004, 126 (05) :1287-1292
[10]   Do statins cause cancer? A meta-analysis of large randomized clinical trials [J].
Bjerre, LM ;
LeLorier, J .
AMERICAN JOURNAL OF MEDICINE, 2001, 110 (09) :716-723